SAB Biotherapeutics, Inc. (SABSW) Financial Statements (2025 and earlier)

Company Profile

Business Address 777 W 41ST ST
MIAMI BEACH, FL 33140
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:20,76156,56615,04739,54585
Cash and cash equivalent8,89856,56615,04733,20785
Short-term investments11,863    
Other undisclosed cash, cash equivalents, and short-term investments    6,338 
Receivables   5,5578,011 
Prepaid expense   1,4942,6362
Other undisclosed current assets3,0322,341   
Total current assets:23,79258,90722,09750,19287
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization3,5833,6703,8974,019 
Operating lease, right-of-use asset9701,2781,1922,615 
Property, plant and equipment15,36819,73723,25124,314 
Deferred costs     235
Other undisclosed noncurrent assets482350468  
Total noncurrent assets:20,40325,03428,80730,949235
TOTAL ASSETS:44,19583,94150,90581,141322
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,4092,4175,2566,149156
Accounts payable1,6959463,6794,459 
Accrued liabilities4,7141,4721,5771,690156
Deferred revenue  1,322 100 
Debt4181,1839051,958 
Due to related parties  150
Other undisclosed current liabilities1,1525,8918,83118,248 
Total current liabilities:7,98010,81314,99326,455306
Noncurrent Liabilities
Long-term debt and lease obligation3,2763,4184,1713,762 
Long-term debt, excluding current maturities   542  
Finance lease, liability3,2763,4183,6303,762 
Liabilities, other than long-term debt6,97012,41068212,373 
Operating lease, liability5816363611,653 
Derivative instruments and hedges, liabilities6,38911,77432110,720 
Total noncurrent liabilities:10,24615,8284,85316,136 
Total liabilities:18,22626,64219,84742,591306
Equity
Equity, attributable to parent25,97057,29931,05838,55016
Preferred stock00   
Common stock11540
Treasury stock, value(5,521)(5,521)(5,521)  
Additional paid in capital155,794152,85784,44467,67525
Accumulated other comprehensive income (loss)(135)26   
Accumulated deficit(124,169)(90,064)(47,870)(29,129)(9)
Total equity:25,97057,29931,05838,55016
TOTAL LIABILITIES AND EQUITY:44,19583,94150,90581,141322

Income Statement (P&L) ($ in thousands)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues1,3222,23923,90460,876 
Gross profit:1,3222,23923,90460,876 
Operating expenses(44,233)(40,314)(52,822)(74,269) 
Operating loss:(42,911)(38,075)(28,918)(13,393) 
Nonoperating income (expense)8,805(4,118)10,2025 
Other nonoperating income2,453435345 
Interest and debt expense(318)(315)(302)371 
Loss from continuing operations before equity method investments, income taxes:(34,424)(42,509)(19,017)(13,017) 
Other undisclosed income (loss) from continuing operations before income taxes 315302(4,128) 
Loss from continuing operations before income taxes:(34,424)(42,194)(18,715)(17,145) 
Income tax expense   (26)  
Net loss:(34,424)(42,194)(18,741)(17,145) 
Other undisclosed net income attributable to parent318    
Net loss available to common stockholders, diluted:(34,105)(42,194)(18,741)(17,145) 

Comprehensive Income ($ in thousands)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(34,424)(42,194)(18,741)(17,145) 
Comprehensive loss:(34,424)(42,194)(18,741)(17,145) 
Comprehensive income, net of tax, attributable to noncontrolling interest1    
Other undisclosed comprehensive income, net of tax, attributable to parent15626   
Comprehensive loss, net of tax, attributable to parent:(34,267)(42,167)(18,741)(17,145) 

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: